Use of integrated SPECT/CT imaging for tumor dosimetry in I-131 radioimmunotherapy: a pilot patient study.
Integrated systems combining functional (single-photon emission computed tomography; SPECT) imaging with anatomic (computed tomography; CT) imaging have the potential to greatly improve the accuracy of dose estimation in radionuclide therapy. In this article, we present the methodology for highly patient-specific tumor dosimetry by utilizing such a system and apply it to a pilot study of 4 follicular lymphoma patients treated with I-131 tositumomab. SPECT quantification included three-dimensional ordered-subset expectation-maximization reconstruction and CT-defined tumor outlines at each time point. SPECT/CT images from multiple time points were coupled to a Monte Carlo algorithm to calculate a mean tumor dose that incorporated measured changes in tumor volume. The tumor shrinkage, defined as the difference between volumes drawn on the first and last CT scan (a typical time period of 15 days) was in the range 5%-49%. The therapy-delivered mean tumor-absorbed dose was in the range 146-334 cGy. For comparison, the therapy dose was also calculated by assuming a static volume from the initial CT and was found to underestimate this dose by up to 47%. The agreement between tracer-predicted and therapy-delivered tumor-absorbed dose was in the range 7%-21%. In summary, malignant lymphomas can have dramatic tumor regression within days of treatment, and advanced imaging methods allow for a highly patient-specific tumor-dosimetry calculation that accounts for this regression.
Dewaraja
Yuni K
YK
Division of Nuclear Medicine, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA. yuni@umich.edu
Wilderman
Scott J
SJ
Koral
Kenneth F
KF
Kaminski
Mark S
MS
Avram
Anca M
AM
D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008224:Lymphoma, Follicular / Q000000981:diagnostic imaging / Q000378:metabolism / Q000532:radiotherapy*; D010865:Pilot Projects; D016499:Radioimmunotherapy / Q000379:methods*; D011874:Radiometry / Q000379:methods; D011879:Radiotherapy Dosage; D011880:Radiotherapy Planning, Computer-Assisted / Q000379:methods; D015899:Tomography, Emission-Computed, Single-Photon / Q000295:instrumentation / Q000379:methods; D014057:Tomography, X-Ray Computed / Q000379:methods
D000911:Antibodies, Monoclonal; D007457:Iodine Radioisotopes; C119496:tositumomab I-131
Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):4003S-6S
14506200
J Nucl Med. 2003 Feb;44(2):260-8
12571219
N Engl J Med. 2005 Feb 3;352(5):441-9
15689582
Rofo. 2002 Dec;174(12):1570-6
12471531
J Nucl Med. 1996 Dec;37(12):1970-5
8970516
Cancer Biother Radiopharm. 2002 Feb;17(1):83-99
11915176
J Nucl Med. 1999 Aug;40(8):1317-26
10450684
Med Phys. 1993 Nov-Dec;20(6):1667-74
8309439
IEEE Trans Nucl Sci. 2007 Feb 17;54(1):146-151
20305792
Phys Med Biol. 2007 Feb 7;52(3):777-90
17228120
Phys Med Biol. 2006 Jul 7;51(13):R187-202
16790903
J Nucl Med. 2007 Jun;48(6):1008-16
17504874
J Clin Oncol. 1998 Oct;16(10):3246-56
9779698
J Nucl Med. 2003 Aug;44(8):1322-9
12902424
Eur J Nucl Med Mol Imaging. 2005 Apr;32(4):458-69
15821965
IEEE Trans Nucl Sci. 2006;53(1):181
20104252
Med Phys. 1994 Jul;21(7):1157-62
7968849
J Nucl Med. 2005 May;46(5):840-9
15872359
J Nucl Med. 2010 Apr;51(4):654-9
20237032
Phys Med Biol. 2000 Aug;45(8):2263-91
10958194
Clin Cancer Res. 2004 Dec 1;10(23):7792-8
15585610
J Nucl Med. 2006 Sep;47(9):1406-12
16954546
Med Phys. 1998 Jan;25(1):85-91
9472830
J Clin Oncol. 1996 Jul;14(7):1974-81
8683227
J Nucl Med. 2003 Mar;44(3):457-64
12621015